2 p.m., and Dec. 9, 7:30 a.m.).
Personalized medicine: Society-funded researchers are developing new
tests to distinguish biological traits (biomarkers) in cancers to identify
patients who are most likely to benefit from a particular treatment and
enable doctors to personalize treatment.
-- Deoxycytidine Kinase Genotype Includes Leukemia Cell Concentration of
Cytarabine 5-Triphosphate in Pediatric AML Patients, Varsha Gandhi,
Ph.D., M.D. Anderson Cancer Center, (Monday, Dec. 10, 8 a.m.).
-- Comprehensive Biomarker and Genomic Analysis Identifies p53 Status as
Major Determinant of Response to MDM2 Inhibitors in Chronic Lymphocytic
Leukemia, Shaomeng Wang, Ph.D., University of Michigan, (Dec. 10, 7:45
-- IgVH Mutational Status Does Not Affect Complete Remission Rate But Is
Associated with Reduced Remission Duration in CLL Patients Treated with
Fludarabine, Cyclophosphamide and Rituximab (FCR)-based Therapy, Thomas
Kipps, M.D., Ph.D., University of California, San Diego, (Tuesday,
Dec. 11, 8 a.m.).
Prior to the start of ASH, the Society will host this year's Marshall A. Lichtman Research Symposium, Chronic Lymphocytic Leukemia as a Model of Translational Research, on Friday, Dec. 7, 7 a.m., at the Omni Hotel at CNN Center in Atlanta. The program will feature several Society-funded researchers discussing all aspects of CLL, from causes to novel treatments.
About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society, headquartered in White Plains, NY,
with 68 chapters in the United States and Canada, is the world's largest
voluntary health organization dedicated to funding blood cancer research
and providing education and patient services. The Society's mission: Cure
leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality
|SOURCE The Leukemia & Lymphoma Society|
Copyright©2007 PR Newswire.
All rights reserved